SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin trades with traction on the bourses

11 Dec 2013 Evaluate

Lupin is currently trading at Rs. 875.50, up by 3.05 points or 0.35% from its previous closing of Rs. 872.45 on the BSE.

The scrip opened at Rs. 876.00 and has touched a high and low of Rs. 882.90 and Rs. 873.00 respectively. So far 36,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 946.35 on 11-Oct-2013 and a 52 week low of Rs. 569.00 on 01-Mar-2013.

Last one week high and low of the scrip stood at Rs. 882.90 and Rs. 851.25 respectively. The current market cap of the company is Rs. 39,222 crore.

The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.

Pharma Major Lupin (Lupin) has received final approval for its Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg / 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of ViiV Healthcare's (ViiV)Trizivir Tablets, 300 mg (base) / 150 mg / 300mg.

Lupin's Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300 mg (base) / 150 mg/ 300 mg is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Lupin was the first applicant to file an ANDA for Trizivir Tablets and as such will be entitled to 180 days of marketing exclusivity.

Trizivir Tablets, 300 mg (base) / 150 mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).  

Lupin Share Price

2328.60 4.35 (0.19%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×